Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UTAA91
- Development stage
- Phase 1
- Lead developer
- PersonGen BioTherapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UTAA91 is an investigational cellular therapy product classified as a γ-δ T cell therapy that acts as a modulator of **CD19** (B-lymphocyte antigen CD19). It is being developed for the treatment of immune-mediated diseases, particularly **refractory moderate-to-severe systemic sclerosis (scleroderma)** and **rheumatoid arthritis** in patients who have not responded to standard treatments. The primary objective of current early-phase clinical studies is to evaluate the safety of UTAA91 injection. The therapy is being developed by PersonGen BioTherapeutics (Suzhou) and is currently being tested in early clinical trials sponsored by Wuhan Union Hospital and PersonGen BioTherapeutics (Suzhou)[1][3][4][5][6][9].
02
Targets
Beyond the preview
Go deeper on UTAA91.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTAA91.